Key result
Peptide inhibitor 229E-HR2P effectively inhibits HCoV-229E spike-mediated cell fusion and live virus infection.
Population
In vitro cell models and a mouse model for HCoV-229E infection
Design
Preclinical
Authors
Loading...
Hypothesis-generating for 229E-HR2P against endemic coronaviruses; leaves open human efficacy and safety data.
The peptide 229E-HR2P demonstrates potent in vitro and in vivo fusion-inhibitory activity against HCoV-229E, representing a promising candidate for antiviral development.
Xia et al. (2018) studied HCoV-229E infection. 229E-HR1P and 229E-HR2P was evaluated on Inhibition of HCoV-229E spike protein-mediated cell-cell fusion and viral infection. The peptide-based membrane fusion inhibitor 229E-HR2P effectively inhibited HCoV-229E spike protein-mediated cell-cell fusion (IC50 0.3 µM) and live virus infection (IC50 1.7 µM).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: